Panels A and B show Kaplan–Meier models of progression-free survival and overall survival, respectively, according to DLBCL genetic subtype. Panels C and D show Kaplan–Meier models of progression-free survival and overall survival, respectively, among patients with ABC DLBCL according to genetic subtype and including patients with non-subtyped ABC cases as “other ABC.” Panel E shows a Kaplan–Meier model of overall survival among patients with GCB DLBCL cases belonging to the EZB subtype or not (“other GCB”). R-CHOP denotes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.